SCHEMBL2015506

SCHEMBL2015506

COC(=O)Oc1ccc(F)cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
KDM4E B2RXH2 4/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 1/20 0.45
CUL4A Q13619 1/20 0.44
MAPT P10636 6/20 0.43
ALDH1A1 P00352 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
HTT P42858 4/20 0.42
JAK2 O60674 1/20 0.42
GAA P10253 1/20 0.42
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RAB9A P51151 2/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
NPC1 O15118 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9444983 0.89 PKM (0.59) PKMKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL30307579 0.82 PKM (0.56) PKMKDM4EHPGDHSD17B10MAPT
SCHEMBL23388820 0.82 ALDH1A1 (0.50) KDM4EHPGDHSD17B10CUL4AMAPT
SCHEMBL513372 0.82 PKM (0.56) PKMKDM4EHPGDHSD17B10MAPT
SCHEMBL29750502 0.82 ALDH1A1 (0.50) KDM4EHPGDHSD17B10CUL4AMAPT
SCHEMBL7214442 0.82 KDM4E (0.47) KDM4EHPGDHSD17B10MAPTALDH1A1
SCHEMBL6382109 0.82 PKM (0.53) PKMKDM4ECUL4AMAPTSMN1; SMN2
SCHEMBL31316398 0.81 PKM (0.55) PKMKDM4EHPGDHSD17B10MAPT
SCHEMBL23887370 0.81 PKM (0.55) PKMKDM4EHPGDHSD17B10MAPT
SCHEMBL1100780 0.81 KDM4E (0.46) KDM4EHPGDHSD17B10MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078136-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2026-03-19 US disclosed
US-20240368198-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2024-11-07 US disclosed
US-20240109922-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2024-04-04 US disclosed
US-11248010-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
EP-3440057-B1 SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES PROTEOSTASIS THERAPEUTICS INC (US) 2021-09-22 EP disclosed
US-20210061823-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. 2021-03-04 US disclosed
US-10662207-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2020-05-26 US disclosed
US-20190153000-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. 2019-05-23 US disclosed
EP-3440057-A1 SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES Proteostasis Therapeutics, Inc. (US) 2019-02-13 EP disclosed
WO-2017177124-A1 SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-12 WO disclosed
US-20040005986-A1 Pyridazin-3-one derivatives, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2004-01-08 US disclosed
US-6482773-B1 Pyridazin-3-one derivatives, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-11-19 US disclosed
US-6348628-B1 HYDRAZONE HERBICIDE INTERMEDIATES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-19 US disclosed
US-6090753-A 2-(SUBSTITUTED PHENYL), 5-HALOALKYL-PYRIDAZIN-3-ONE DERIVATIVES AS HERBICIDES; CONTROLLING WEEDS, METHOD OF MAKING BY REACTING A HYDRAZONE DERIVATIVE WITH A SPECIFIED PHOSPHORUS COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2000-07-18 US disclosed
EP-0850227-A1 PYRIDAZIN-3-ONE DERIVATIVES, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-07-01 EP disclosed
WO-1997007104-A1 PYRIDAZIN-3-ONE DERIVATIVES, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-02-27 WO disclosed
US-4818276-A Herbicidal 1-aryl-Δ2 -1,2,4-triazolin-5-ones FMC CORPORATION (US) 1989-04-04 US disclosed
EP-0231176-A1 HERBICIDAL 1-ARYL-$g(d)?2 -1,2,4-TRIAZOLIN-5-ONES FMC Corporation (US) 1987-08-12 EP disclosed
WO-1987000730-A1 HERBICIDAL 1-ARYL-delta2-1,2,4-TRIAZOLIN-5-ONES FMC CORPORATION (US) 1987-02-12 WO disclosed
CN-85106905-A Contain 1-aryl-Δ 2-1,2,4, weedicide of-triazoline-5-ketone and preparation method thereof 1987-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109922-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G PKM 2993/4885KDM4E 4572/4885HPGD 2098/4885
US-20240368198-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G PKM 2993/4885KDM4E 4572/4885HPGD 2098/4885
US-11248010-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G PKM 2993/4885KDM4E 4572/4885HPGD 2098/4885
US-20190153000-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G PKM 2993/4885KDM4E 4572/4885HPGD 2098/4885
US-20040005986-A1 Pyridazin-3-one derivatives, their use, and intermediates for their production Q6ZSR9, HDHD5, CBR3 PKM 1238/4885KDM4E 1347/4885HPGD 393/4885
US-20210061823-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G PKM 2993/4885KDM4E 4572/4885HPGD 2098/4885
US-20260078136-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1A PKM 1951/4885KDM4E 2582/4885HPGD 2634/4885
US-10662207-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G PKM 2993/4885KDM4E 4572/4885HPGD 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.